Publication Information

{'id': 'https://openalex.org/W4311747477', 'doi': 'https://doi.org/10.1093/ofid/ofac492.1854', 'title': '2236. Effectiveness of TBP-PI-HBr in Patients with Instrumentation, Anatomic or Functional Abnormalities: Secondary Analysis from ADAPT-PO', 'display_name': '2236. Effectiveness of TBP-PI-HBr in Patients with Instrumentation, Anatomic or Functional Abnormalities: Secondary Analysis from ADAPT-PO', 'publication_year': 2022, 'publication_date': '2022-12-01', 'ids': {'openalex': 'https://openalex.org/W4311747477', 'doi': 'https://doi.org/10.1093/ofid/ofac492.1854'}, 'language': 'en', 'primary_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.1093/ofid/ofac492.1854', 'pdf_url': 'https://academic.oup.com/ofid/article-pdf/9/Supplement_2/ofac492.1854/47895969/ofac492.1854.pdf', 'source': {'id': 'https://openalex.org/S2735126445', 'display_name': 'Open Forum Infectious Diseases', 'issn_l': '2328-8957', 'issn': ['2328-8957'], 'is_oa': True, 'is_in_doaj': True, 'is_core': True, 'host_organization': 'https://openalex.org/P4310311648', 'host_organization_name': 'Oxford University Press', 'host_organization_lineage': ['https://openalex.org/P4310311647', 'https://openalex.org/P4310311648'], 'host_organization_lineage_names': ['University of Oxford', 'Oxford University Press'], 'type': 'journal'}, 'license': 'cc-by', 'license_id': 'https://openalex.org/licenses/cc-by', 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref'], 'open_access': {'is_oa': True, 'oa_status': 'gold', 'oa_url': 'https://academic.oup.com/ofid/article-pdf/9/Supplement_2/ofac492.1854/47895969/ofac492.1854.pdf', 'any_repository_has_fulltext': True}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5108773992', 'display_name': 'Angela K. Talley', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210160063', 'display_name': 'Spero Therapeutics (United States)', 'ror': 'https://ror.org/05fxq1221', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I4210160063']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Angela K Talley', 'raw_affiliation_strings': ['Spero Therapeutics , Cambridge, Massachusetts'], 'affiliations': [{'raw_affiliation_string': 'Spero Therapeutics , Cambridge, Massachusetts', 'institution_ids': ['https://openalex.org/I4210160063']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5031780287', 'display_name': 'Paul B. Eckburg', 'orcid': 'https://orcid.org/0000-0001-6133-9057'}, 'institutions': [{'id': 'https://openalex.org/I4210160063', 'display_name': 'Spero Therapeutics (United States)', 'ror': 'https://ror.org/05fxq1221', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I4210160063']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Paul B Eckburg', 'raw_affiliation_strings': ['Spero Therapeutics , Cambridge, Massachusetts'], 'affiliations': [{'raw_affiliation_string': 'Spero Therapeutics , Cambridge, Massachusetts', 'institution_ids': ['https://openalex.org/I4210160063']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5063814702', 'display_name': 'Ian A. Critchley', 'orcid': 'https://orcid.org/0000-0003-0981-0758'}, 'institutions': [{'id': 'https://openalex.org/I4210160063', 'display_name': 'Spero Therapeutics (United States)', 'ror': 'https://ror.org/05fxq1221', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I4210160063']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Ian A Critchley', 'raw_affiliation_strings': ['Spero Therapeutics , Cambridge, Massachusetts'], 'affiliations': [{'raw_affiliation_string': 'Spero Therapeutics , Cambridge, Massachusetts', 'institution_ids': ['https://openalex.org/I4210160063']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5063814702', 'display_name': 'Ian A. Critchley', 'orcid': 'https://orcid.org/0000-0003-0981-0758'}, 'institutions': [{'id': 'https://openalex.org/I4210160063', 'display_name': 'Spero Therapeutics (United States)', 'ror': 'https://ror.org/05fxq1221', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I4210160063']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Ian A Critchley', 'raw_affiliation_strings': ['Spero Therapeutics , Cambridge, Massachusetts'], 'affiliations': [{'raw_affiliation_string': 'Spero Therapeutics , Cambridge, Massachusetts', 'institution_ids': ['https://openalex.org/I4210160063']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5076899486', 'display_name': 'Gary E Moore', 'orcid': None}, 'institutions': [], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Gary E Moore', 'raw_affiliation_strings': ['Moore Computing Services, Inc. , Little Rock, Arkansas'], 'affiliations': [{'raw_affiliation_string': 'Moore Computing Services, Inc. , Little Rock, Arkansas', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5049363722', 'display_name': 'Nivedita Bhatt', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210160063', 'display_name': 'Spero Therapeutics (United States)', 'ror': 'https://ror.org/05fxq1221', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I4210160063']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Nivedita Bhatt', 'raw_affiliation_strings': ['Spero Therapeutics , Cambridge, Massachusetts'], 'affiliations': [{'raw_affiliation_string': 'Spero Therapeutics , Cambridge, Massachusetts', 'institution_ids': ['https://openalex.org/I4210160063']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5066493413', 'display_name': 'Lori A Muir', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210160063', 'display_name': 'Spero Therapeutics (United States)', 'ror': 'https://ror.org/05fxq1221', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I4210160063']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Lori A Muir', 'raw_affiliation_strings': ['Spero Therapeutics , Cambridge, Massachusetts'], 'affiliations': [{'raw_affiliation_string': 'Spero Therapeutics , Cambridge, Massachusetts', 'institution_ids': ['https://openalex.org/I4210160063']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5066493413', 'display_name': 'Lori A Muir', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210160063', 'display_name': 'Spero Therapeutics (United States)', 'ror': 'https://ror.org/05fxq1221', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I4210160063']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Lori A Muir', 'raw_affiliation_strings': ['Spero Therapeutics , Cambridge, Massachusetts'], 'affiliations': [{'raw_affiliation_string': 'Spero Therapeutics , Cambridge, Massachusetts', 'institution_ids': ['https://openalex.org/I4210160063']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5060861947', 'display_name': 'David Melnick', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210160063', 'display_name': 'Spero Therapeutics (United States)', 'ror': 'https://ror.org/05fxq1221', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I4210160063']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'David Melnick', 'raw_affiliation_strings': ['Spero Therapeutics , Cambridge, Massachusetts'], 'affiliations': [{'raw_affiliation_string': 'Spero Therapeutics , Cambridge, Massachusetts', 'institution_ids': ['https://openalex.org/I4210160063']}]}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 1, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': {'value': 3064, 'currency': 'USD', 'value_usd': 3064, 'provenance': 'doaj'}, 'apc_paid': {'value': 3064, 'currency': 'USD', 'value_usd': 3064, 'provenance': 'doaj'}, 'fwci': 0.0, 'has_fulltext': True, 'fulltext_origin': 'pdf', 'cited_by_count': 0, 'citation_normalized_percentile': {'value': 0.0, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 0, 'max': 60}, 'biblio': {'volume': '9', 'issue': 'Supplement_2', 'first_page': None, 'last_page': None}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T11036', 'display_name': 'Antibiotics Pharmacokinetics and Efficacy', 'score': 0.9995, 'subfield': {'id': 'https://openalex.org/subfields/2736', 'display_name': 'Pharmacology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T11036', 'display_name': 'Antibiotics Pharmacokinetics and Efficacy', 'score': 0.9995, 'subfield': {'id': 'https://openalex.org/subfields/2736', 'display_name': 'Pharmacology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11232', 'display_name': 'Urinary Tract Infections Management', 'score': 0.9985, 'subfield': {'id': 'https://openalex.org/subfields/2713', 'display_name': 'Epidemiology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10147', 'display_name': 'Antibiotic Resistance in Bacteria', 'score': 0.9924, 'subfield': {'id': 'https://openalex.org/subfields/1313', 'display_name': 'Molecular Medicine'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/clinical-endpoint', 'display_name': 'Clinical endpoint', 'score': 0.5878879}], 'concepts': [{'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.9102427}, {'id': 'https://openalex.org/C203092338', 'wikidata': 'https://www.wikidata.org/wiki/Q1340863', 'display_name': 'Clinical endpoint', 'level': 3, 'score': 0.5878879}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.57952076}, {'id': 'https://openalex.org/C77411442', 'wikidata': 'https://www.wikidata.org/wiki/Q181100', 'display_name': 'Urinary system', 'level': 2, 'score': 0.5706061}, {'id': 'https://openalex.org/C2908647359', 'wikidata': 'https://www.wikidata.org/wiki/Q2625603', 'display_name': 'Population', 'level': 2, 'score': 0.50407994}, {'id': 'https://openalex.org/C126894567', 'wikidata': 'https://www.wikidata.org/wiki/Q105650', 'display_name': 'Urology', 'level': 1, 'score': 0.45224652}, {'id': 'https://openalex.org/C90924648', 'wikidata': 'https://www.wikidata.org/wiki/Q120569', 'display_name': 'Gastroenterology', 'level': 1, 'score': 0.45140916}, {'id': 'https://openalex.org/C168563851', 'wikidata': 'https://www.wikidata.org/wiki/Q1436668', 'display_name': 'Randomized controlled trial', 'level': 2, 'score': 0.37523216}, {'id': 'https://openalex.org/C141071460', 'wikidata': 'https://www.wikidata.org/wiki/Q40821', 'display_name': 'Surgery', 'level': 1, 'score': 0.3560331}, {'id': 'https://openalex.org/C99454951', 'wikidata': 'https://www.wikidata.org/wiki/Q932068', 'display_name': 'Environmental health', 'level': 1, 'score': 0.0}], 'mesh': [], 'locations_count': 2, 'locations': [{'is_oa': True, 'landing_page_url': 'https://doi.org/10.1093/ofid/ofac492.1854', 'pdf_url': 'https://academic.oup.com/ofid/article-pdf/9/Supplement_2/ofac492.1854/47895969/ofac492.1854.pdf', 'source': {'id': 'https://openalex.org/S2735126445', 'display_name': 'Open Forum Infectious Diseases', 'issn_l': '2328-8957', 'issn': ['2328-8957'], 'is_oa': True, 'is_in_doaj': True, 'is_core': True, 'host_organization': 'https://openalex.org/P4310311648', 'host_organization_name': 'Oxford University Press', 'host_organization_lineage': ['https://openalex.org/P4310311647', 'https://openalex.org/P4310311648'], 'host_organization_lineage_names': ['University of Oxford', 'Oxford University Press'], 'type': 'journal'}, 'license': 'cc-by', 'license_id': 'https://openalex.org/licenses/cc-by', 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, {'is_oa': True, 'landing_page_url': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752703', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S2764455111', 'display_name': 'PubMed Central', 'issn_l': None, 'issn': None, 'is_oa': True, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': 'acceptedVersion', 'is_accepted': True, 'is_published': False}], 'best_oa_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.1093/ofid/ofac492.1854', 'pdf_url': 'https://academic.oup.com/ofid/article-pdf/9/Supplement_2/ofac492.1854/47895969/ofac492.1854.pdf', 'source': {'id': 'https://openalex.org/S2735126445', 'display_name': 'Open Forum Infectious Diseases', 'issn_l': '2328-8957', 'issn': ['2328-8957'], 'is_oa': True, 'is_in_doaj': True, 'is_core': True, 'host_organization': 'https://openalex.org/P4310311648', 'host_organization_name': 'Oxford University Press', 'host_organization_lineage': ['https://openalex.org/P4310311647', 'https://openalex.org/P4310311648'], 'host_organization_lineage_names': ['University of Oxford', 'Oxford University Press'], 'type': 'journal'}, 'license': 'cc-by', 'license_id': 'https://openalex.org/licenses/cc-by', 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'sustainable_development_goals': [{'id': 'https://metadata.un.org/sdg/1', 'score': 0.44, 'display_name': 'No poverty'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W3179965273', 'https://openalex.org/W3139914494', 'https://openalex.org/W2373885168', 'https://openalex.org/W2362391294', 'https://openalex.org/W2355769538', 'https://openalex.org/W2151333571', 'https://openalex.org/W2112436308', 'https://openalex.org/W2081816252', 'https://openalex.org/W1980112510', 'https://openalex.org/W1556819926'], 'abstract_inverted_index': {'Abstract': [0], 'Background': [1], 'Tebipenem': [2], 'pivoxil': [3], 'hydrobromide': [4], '(TBP-PI-HBr)': [5], 'is': [6], 'an': [7], 'oral': [8, 26, 94, 111, 289], 'carbapenem': [9], 'with': [10, 36, 43, 78, 104, 144, 146, 214, 226, 237, 255, 276], 'activity': [11], 'against': [12], 'Enterobacterales': [13], 'uropathogens,': [14], 'including': [15], 'drug': [16], 'resistant': [17], 'strains.': [18], 'The': [19, 119], 'ADAPT-PO': [20, 73, 84], 'trial': [21, 92], 'demonstrated': [22], 'the': [23, 133, 165, 269], 'non-inferiority': [24], 'of': [25, 72, 162], 'TBP-PI-HBr': [27, 95, 112, 166, 196, 227, 290], 'vs.': [28, 96, 231], 'intravenous': [29], '(IV)': [30], 'ertapenem': [31], '(ERT)': [32], 'in': [33, 76, 99, 132, 164, 193, 206, 250, 253, 307], 'treating': [34], 'patients': [35, 77, 103, 143, 163, 213, 254, 275, 297, 313], 'cUTI': [37, 80, 150, 274], 'and/or': [38, 52, 187], 'acute': [39], 'pyelonephritis': [40], '(AP).': [41], 'Patients': [42, 106], 'certain': [44], 'anatomical': [45], 'disorders,': [46], 'functional': [47, 202], '(metabolic': [48], 'or': [49, 113], 'neurological)': [50], 'disorders': [51], 'urinary': [53, 188], 'tract': [54], 'instrumentation': [55, 190], '(i.e.,': [56], 'indwelling': [57], 'catheters)': [58], 'are': [59], 'at': [60, 147, 153, 220, 244, 283, 299], 'increased': [61], 'risk': [62, 81, 151, 173, 183, 216, 239, 260, 278, 301, 316], 'for': [63, 116, 280, 302], 'poor': [64], 'outcomes': [65, 75, 139, 285], 'and': [66, 129, 160, 167, 175, 178, 197, 209, 224, 228, 233, 248, 257, 291], 'recurrent': [67, 303], 'bacteriuria.': [68, 304], 'This': [69], 'secondary': [70], 'analysis': [71], 'evaluated': [74], 'various': [79], 'factors.': [82, 184, 240, 317], 'Methods': [83], 'was': [85, 123, 222], 'a': [86], 'Phase': [87], '3': [88], 'multinational,': [89], 'double-blind,': [90], 'double-dummy': [91], 'evaluating': [93], 'IV': [97, 114, 292], 'ERT': [98, 115, 168, 200], '1372': [100], 'hospitalized': [101], 'adult': [102], 'cUTI/AP.': [105], 'were': [107, 140, 191, 204, 246, 265, 286, 298, 310], 'randomized': [108], '1:1': [109], 'to': [110], '7-10': [117], 'days.': [118], 'primary': [120], 'efficacy': [121], 'endpoint': [122], 'overall': [124, 218], 'response': [125, 219, 242], '(composite': [126], 'favorable': [127], 'clinical': [128], 'microbiologic': [130, 263], 'response)': [131], 'microbiological': [134], 'intent-to-treat': [135], '(micro-ITT)': [136], 'population.': [137], 'Overall': [138, 305], 'assessed': [141], 'among': [142, 235, 312], 'identified': [145], 'least': [148], 'one': [149], 'factor': [152, 174, 279], 'baseline.': [154], 'Results': [155], 'At': [156], 'baseline,': [157, 284], '382/449': [158], '(85.1%)': [159], '361/449(86.2%)': [161], 'arms,': [169], 'respectively': [170], 'had': [171, 181], '≥1': [172, 215, 277], '289': [176], '(64.4%)': [177], '268': [179], '(64.2%)': [180], '≥2': [182], 'Anatomical': [185], 'abnormalities': [186, 203], 'track': [189], 'present': [192, 205], '252': [194], '(56.1%)': [195], '242': [198], '(57.8%)': [199], 'patients;': [201], '90': [207], '(20.0%)': [208], '85(20.3%)': [210], 'respectively).': [211], 'Among': [212], 'factor,': [217], 'TOC': [221, 245], '56.3%': [223], '59.6%': [225], 'ERT,': [229], 'respectively,': [230], '73.1%': [232], '74.1%': [234], 'those': [236], 'no': [238], 'Clinical': [241], 'rates': [243], 'high': [247], 'similar': [249], 'both': [251, 308], 'arms': [252], '(≥92.9%)': [256], 'without': [258, 314], '(≥91.4%)': [259], 'factors': [261], 'whereas': [262], 'responses': [264, 306], 'more': [266], 'variable': [267], 'between': [268, 288], '2': [270], 'subsets.': [271], 'Conclusion': [272], 'In': [273], 'complicated': [281], 'disease': [282], 'comparable': [287], 'ERT.': [293], 'As': [294], 'expected,': [295], 'these': [296, 315], 'higher': [300, 311], 'groups': [309], 'Disclosures': [318], 'Angela': [319], 'K.': [320], 'Talley,': [321], 'MD,': [322, 331, 390], 'Spero': [323, 341, 350, 359, 365, 374, 383, 391], 'Therapeutics:': [324, 326, 333, 335, 342, 344, 351, 353, 360, 366, 368, 375, 377, 384, 386, 392, 394], 'Employee|Spero': [325, 343, 352, 367, 376, 385, 393], 'Stocks/Bonds': [327, 345, 354, 369, 378, 387], 'Paul': [328], 'B.': [329], 'Eckburg,': [330], 'AN2': [332], 'Stocks/Bonds|Spero': [334], 'Advisor/Consultant': [336, 361], 'Ian': [337, 346], 'A.': [338, 347, 371, 380], 'Critchley,': [339, 348], 'PhD,': [340, 349, 358, 364], 'Gary': [355], 'E.': [356], 'Moore,': [357], 'Nivedita': [362], 'Bhatt,': [363], 'Lori': [370, 379], 'Muir,': [372, 381], 'B.Sc.,': [373, 382], 'David': [388], 'Melnick,': [389], 'Stocks/Bonds.': [395]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W4311747477', 'counts_by_year': [], 'updated_date': '2024-12-24T04:07:39.845922', 'created_date': '2022-12-28'}